Brought to you by 
Natera to launch Signatera test in China on BGI's DNBseq NGS platform
12 Mar 2019
Executive Summary
BGI Genomics Co. Ltd. will commercialize in China Natera Inc.'s Signatera minimal residual disease (MRD) and molecular monitoring test. The companies will also partner on the development of reproductive health tests in certain territories.
Deal Industry
- In Vitro Diagnostics
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Natera to launch Signatera test in China on BGI's DNBseq NGS platform
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice